Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)

Blood (2024) 144 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2024-194925

Published: 2024

Journal Articles

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Blood (2023) 142 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2023-182266

Published: 2023

Journal Articles

Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

Cecilia Bonolo De Campos, Chantal McCabe, Laura Ann Bruins, Daniel R. O'Brien, Sochilt Brown, Cristine Allmer, Yuan Xiao Zhu, Kari G Rabe, Sameer A. Parikh, Neil E. Kay, James R. Cerhan, Laura Z Rassenti, Richard R. Furman, J. Brice Weinberg, Danielle Brander, Marta Chesi, Susan L. Slager, Esteban Braggio

Blood (2022) 140 (Supplement 1): 4135–4136.

https://doi.org/10.1182/blood-2022-170944

Published: 2022

Journal Articles

TP53 Aberrations and Outcomes in MBL and Untreated CLL

Rosalie Griffin Waller, Julia E. Wiedmeier, Nicholas J. Boddicker, Geffen Kleinstern, Cecilia Bonolo De Campos, Daniel L. Van Dyke, Huihuang Yan, Celine M. Vachon, Daniel R. O'Brien, Cristine Allmer, Kari G. Rabe, James R. Cerhan, Timothy G. Call, Sameer A. Parikh, Neil E. Kay, Esteban Braggio, Susan L. Slager

Blood (2021) 138 (Supplement 1): 2618.

https://doi.org/10.1182/blood-2021-153602

Published: 2021

Journal Articles

Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX)

Celine M. Vachon, PhD, Josiah Murray, Cristine Allmer, BS, Dirk Larson, MS, Aaron D. Norman, MPH, Jason P Sinnwell, MS, Angela Dispenzieri, MD, Geffen Kleinstern, PhD, Robert A. Kyle, MD, S. Vincent Rajkumar, MD, Susan L. Slager, PhD, Shaji K. Kumar, MD, David L. Murray, MDPhD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-142583

Published: 2020

Journal Articles

Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota

Geffen Kleinstern, PhD, Dirk Larson, MS, Cristine Allmer, BS, Aaron D. Norman, MPH, Jason P Sinnwell, MS, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Robert A. Kyle, MD, Susan L. Slager, PhD, Shaji K. Kumar, MD, Celine M. Vachon, PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-136894

Published: 2020

Journal Articles

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Melissa C Larson, MS, Cristine Allmer, BS, Susan L. Slager, PhD, Thomas M. Habermann, MD, Sunnia T Chen, BS, Hector R Villarraga, MD, Joerg Herrmann, MD, Gita Thanarajasingam, MD, Alessia Castellino, MD, Grzegorz Nowakowski, MD, David J Inwards, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2019) 134 (Supplement_1): 422.

https://doi.org/10.1182/blood-2019-127203

Published: 2019

Journal Articles

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)

Blood (2019) 134 (Supplement_1): 69.

https://doi.org/10.1182/blood-2019-129499

Published: 2019

Journal Articles

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Sunnia T Chen, BS, Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Cristine Allmer, BS, Dennis P. Robinson, Grzegorz Nowakowski, MD, Thomas M. Habermann, MD, Susan L Slager, PhD, Carrie A. Thompson, MD, James R. Cerhan, MD PhD

Blood (2019) 134 (Supplement_1): 5215.

https://doi.org/10.1182/blood-2019-128775

Published: 2019

Journal Articles

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

Yucai Wang, Brian K. Link, Thomas E. Witzig, Matthew J. Maurer, Cristine Allmer, Rebecca L. King, Andrew L. Feldman, Thomas M. Habermann, Stephen M. Ansell, Susan L. Slager, James R. Cerhan, Grzegorz S. Nowakowski

Blood (2019) 134 (16): 1289–1297.

https://doi.org/10.1182/blood.2019000858

Published: 2019

Includes: Supplemental data

Journal Articles

Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas

Hidong Kim, MD, Laura Harper, MD, Thomas M. Habermann, MD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Patrick Johnston, Thomas E. Witzig, MD, Cristine Allmer, BS, Matthew J. Maurer, MS, James R. Cerhan, MD PhD, Jason Young, MD, Gita Thanarajasingam, MD

Blood (2018) 132 (Supplement 1): 5401.

https://doi.org/10.1182/blood-2018-99-117711

Published: 2018

Journal Articles

Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era

Alessia Castellino, MD, Melissa C. Larson, MS, Matthew J. Maurer, MS, Susan L. Slager, PhD, Cristine Allmer, BS, Jonathon B. Cohen, MD MS, Andrew L. Feldman, MD, Sergei Syrbu, MD PhD, Brian K. Link, MD, Umar Farooq, MD, David J Inwards, MD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD

Blood (2018) 132 (Supplement 1): 4140.

https://doi.org/10.1182/blood-2018-99-119595

Published: 2018

Journal Articles

Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era

Yucai Wang, MD, Umar Farooq, MD, Brian K. Link, MD, Mehrdad Hefazi, MD, Cristine Allmer, BS, Matthew J. Maurer, MS, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Stephen M. Ansell, MD PhD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD

Blood (2018) 132 (Supplement 1): 454.

https://doi.org/10.1182/blood-2018-99-113213

Published: 2018

Journal Articles

Association of Health Behaviors and Quality of Life in Lymphoma Survivors

Priyanka Pophali, MD, Melissa C. Larson, MS, Dennis P. Robinson, Cristine Allmer, BS, Allison C. Rosenthal, DO, Umar Farooq, MD, Brian K. Link, MD, Matthew J. Maurer, MS, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2018) 132 (Supplement 1): 4838.

https://doi.org/10.1182/blood-2018-99-111738

Published: 2018

Journal Articles

Compliance with Age-Appropriate Screening for Malignancies and Influenza Vaccination in 3-Year Lymphoma Survivors

Priyanka Pophali, MD, Melissa C. Larson, MS, Cristine Allmer, BS, Umar Farooq, MD, Brian K. Link, MD, Matthew J. Maurer, MS, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2018) 132 (Supplement 1): 4791.

https://doi.org/10.1182/blood-2018-99-117822

Published: 2018

Journal Articles

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States

Blood (2018) 132 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2018-99-114281

Published: 2018

Journal Articles

Autoimmune Diseases and Prognosis across Lymphoma Subtypes

Geffen Kleinstern, PhD, Matthew J Maurer, MS, Mark Liebow, MD, Thomas M Habermann, MD, Jean L. Koff, MD, Cristine Allmer, BS, Thomas E Witzig, MD, Grzegorz S Nowakowski, MD, Ivana N Micallef, MD, Patrick B Johnston, MD PhD, David J Inwards, MD, Carrie A Thompson, MD, Andrew L Feldman, MD, Brian K Link, MD, Christopher Flowers, MD, Susan L Slager, PhD, James R. Cerhan, MD PhD

Blood (2017) 130 (Supplement 1): 2159.

https://doi.org/10.1182/blood.V130.Suppl_1.2159.2159

Published: 2017

Journal Articles

The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival

Priyanka Pophali, MD, Melissa C. Larson, M.S., Allison C. Rosenthal, DO, Matthew J Maurer, MS, Jonathon B Cohen, MDMS, Andrew Ip, MD, Christopher Flowers, MD, Brian K Link, MD, Umar Farooq, MD, Andrew L Feldman, MD, Cristine Allmer, BS, Susan L Slager, PhD, Thomas M Habermann, MD, James R. Cerhan, MD PhD, Carrie A Thompson, MD

Blood (2017) 130 (Supplement 1): 914.

https://doi.org/10.1182/blood.V130.Suppl_1.914.914

Published: 2017

Journal Articles

Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis

Carrie A Thompson, MD, Kathleen Yost, PhD, Melissa C. Larson, M.S., Cristine Allmer, BS, Matthew J Maurer, MS, Amylou C. Dueck, PhD, Tait D. Shanafelt, MD, Thomas M Habermann, MD, Allison C. Rosenthal, DO, Umar Farooq, MD, Brian K Link, MD, James R Cerhan, MD PhD

Blood (2017) 130 (Supplement 1): 917.

https://doi.org/10.1182/blood.V130.Suppl_1.917.917

Published: 2017

Journal Articles

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

Blood (2017) 130 (Supplement 1): 4115.

https://doi.org/10.1182/blood.V130.Suppl_1.4115.4115

Published: 2017

NARROW

Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

TP53 Aberrations and Outcomes in MBL and Untreated CLL

Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX)

Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas

Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era

Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era

Association of Health Behaviors and Quality of Life in Lymphoma Survivors

Compliance with Age-Appropriate Screening for Malignancies and Influenza Vaccination in 3-Year Lymphoma Survivors

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States

Autoimmune Diseases and Prognosis across Lymphoma Subtypes

The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival

Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only